Daiichi Sankyo.
Japanese pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 58
What's happening
Earlier this month
-
A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.Some support1 report1 development inside
-
The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Some support8 reports
-
Zevra Therapeutics and Daiichi Sankyo are involved in the competitive healthcare investment space, with Zevra developing products for serious medical conditions.Some support1 report
One to three months ago
-
The Delhi High Court ordered a forensic audit and sought enforcement of an arbitration award against founder-linked entities.Some support3 reports1 development inside
-
Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Some support2 reports
-
Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.Some support2 reports
-
Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.Some support3 reports1 development inside
-
Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.Some support3 reports
-
Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.Some support2 reports
-
Daiichi Sankyo and Shuttle Pharmaceuticals are competing in the pharmaceutical market.Some support1 report
-
The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.Some support2 reports
Gone quiet
No new reports in 90+ days-
Daiichi Sankyo and AstraZeneca are nearing a UK pricing deal for Enhertu, while Morgan Stanley and Bank of America issued recent rating updates.Some support1 report
-
The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.Some support2 reports
-
Daiichi Sankyo is headquartered in Tokyo, Japan.Some support3 reports
-
Daiichi Sankyo is conducting clinical trials across various EU countries.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Daiichi Sankyo
Events traced to Daiichi Sankyo, step by step, newest firstAround Daiichi Sankyo this week
News at the entities that move Daiichi Sankyo most-
AstraZeneca StructuralAstraZeneca plans a $2B facility in Tuas, Singapore, while President Shanmugaratnam conducts a state visit to Sweden.Moves Daiichi Sankyo
-
FDA StructuralLitigation regarding FDA approval process.Moves Daiichi Sankyo
-
Europe StructuralMorgan Stanley issued an underweight rating due to relative stock weakness, while favoring Japanese equities.Moves Daiichi Sankyo
-
Fortis OperationalInflationary concerns are driving central bank policy shifts, leading to short-term rate hikes, while Fortis is expected to increase its dividend payout.Moves Daiichi Sankyo
-
Delhi Shared contextA committee utilized an event in Delhi to promote women's empowerment.Moves Daiichi Sankyo
-
Tokyo Shared contextThe Securities and Futures Commission held a seminar in Tokyo, with Julia Leung representing the SFC's views on market changes.Moves Daiichi Sankyo
Connections
The 14 strongest of 58, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Structural
The companies are engaged in a deep, ongoing partnership for the joint development and commercialization of advanced cancer treatments, including Enhertu and Datroway.
-
Michio Hayashi Structural
A holds the executive office of President for B, defining a formal leadership structure within the company.
-
Fortis Operational
The entities are engaged in an ongoing high-stakes legal dispute concerning shareholding and mandatory tender offer approvals.
-
FDA Structural
The FDA provides the regulatory framework under which Daiichi Sankyo must operate, evidenced by the company's voluntary withdrawal from the BLA investigational program.
-
AstraZeneca Operational
AstraZeneca and Daiichi Sankyo are actively engaged in both co-developing drugs and competing in the HER2-mutant NSCLC treatment market.
-
Innovent Biologics Structural
Exclusive agreement for the commercialization and supply of Vanflyta.
-
NTK Operational
The relationship is characterized by active market competition stemming from litigation regarding the acquisition of shares in the Fortis chain.
-
Fortis Healthcare Transactional
Daiichi Sankyo initiated legal enforcement proceedings over an arbitral award against entities linked to Fortis Healthcare.
Show all 14 connections
-
Europe Structural
Daiichi Sankyo conducts clinical trials utilizing the regulatory and market infrastructure of various European Union countries.
-
Fujitsu Operational
Both companies are major listed entities operating within the competitive landscape of the Japanese market.
-
Tokyo Shared context
Daiichi Sankyo is headquartered in Tokyo.
-
Delhi Shared context
Daiichi Sankyo is involved in an arbitration case held within the jurisdiction of Delhi.
-
Shivinder Mohan Singh Transactional
Shivinder Mohan Singh is involved in arbitration proceedings regarding Daiichi Sankyo.
-
Japan Shared context
Daiichi Sankyo is a global company that is based in Japan.
History
Events by the month they beganSeptember 2026
5 events- A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.
- The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.
- Zevra Therapeutics and Daiichi Sankyo are involved in the competitive healthcare investment space, with Zevra developing products for serious medical conditions.
- Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.
- Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.
August 2026
3 events- The Delhi High Court ordered a forensic audit and sought enforcement of an arbitration award against founder-linked entities.
- Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.
- Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.
July 2026
3 events- Daiichi Sankyo and Shuttle Pharmaceuticals are competing in the pharmaceutical market.
- The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.
- Daiichi Sankyo and AstraZeneca are nearing a UK pricing deal for Enhertu, while Morgan Stanley and Bank of America issued recent rating updates.
Show 1 earlier month
June 2026
4 events- Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.
- The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.
- Daiichi Sankyo is headquartered in Tokyo, Japan.
- Daiichi Sankyo is conducting clinical trials across various EU countries.